At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Sarilumab +1 moredrug
Likely dose
Sarilumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
In Brief
A Phase 2 clinical trial evaluating Sarilumab and Placebo for Sarcoidosis. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoidosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartSep 2019
Primary CompletionJul 2022
Study CompletionSep 2022
TodayJul 2026
First PostedJul 5, 2019
Enrollment StartSep 3, 2019
Primary CompletionJul 26, 2022
Study CompletionSep 9, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.0 years ago
Interventions
Sarilumabdrug
Sarilumab 200 mg administered subcutaneously
Placebodrug
Placebo administered subcutaneously